Kyverna sets IPO range, eyeing $180M haul to fund broad autoimmune CAR-T clinical trial program

Kyverna Therapeutics has laid the foundations for the next major IPO of 2024. Having filed last month, the autoimmune cell therapy biotech set the terms for an offering that could gross around $180 million on Thursday.